Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

Cardiovascular disease

Merck’s Winrevair Cuts Morbidity, Mortality Risk by Over 75% in Phase III PAH Study

Merck continues to build the case for the pulmonary arterial hypertension drug that won FDA approval in 2024.

April 1, 2025

2 min read

Tristan Manalac

Concept of money prize. Vector illustration. Halftone hand holds bouquet of money flowers. Gift prize, donation, earnings, bonus or cashback concept. Retro poster or banner. Creative trend collage.

Funding

AIRNA Hits $155M Series B Haul To Advance RNA Editor for Rare Genetic Disease

AIRNA’s lead candidate AIR-001 works by correcting the most common pathologic mutation driving the rare disease alpha-1 antitrypsin deficiency.

April 1, 2025

2 min read

Tristan Manalac

Robert F Kennedy Jr speaking at the White House

Government

Calls To End Kennedy’s Leadership Follow Marks’ Abrupt Exit

Analysts at financial firm Cantor Fitzgerald are urging President Donald Trump to rethink his appointment of Robert F. Kennedy Jr. as Secretary of Health and Human Services.

April 1, 2025

2 min read

Tristan Manalac

Hand holding pencil erasing an employee. Dismissal or bankrumptcy concept. Vector illustration.

Layoffs

Tenaya Slashes a Third of Workforce To Fund Development of Cardio Gene Therapies

The layoffs will take place throughout 2025 and will mostly affect Tenaya’s research and manufacturing operations. The company is continuing to test its hypertrophic cardiomyopathy gene therapy.

April 1, 2025

2 min read

Tristan Manalac

Climb up, hand help businessman build ladder

Diabetes

Vertex Cuts Diabetes Asset, but Analysts Keen on Phase III Option

Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge loss for Vertex given that the company has a more advanced type 1 diabetes candidate in zimislecel.

March 31, 2025

4 min read

Annalee Armstrong

FDA

Marks’ Sudden Departure From FDA Magnifies Uncertainty, Sends Biopharma Shares Down

The stock market—and biotech insiders—reacted negatively to the allegedly forced resignation of CBER Director Peter Marks, who said RFK Jr. does not seek “truth and transparency” but rather “subservient confirmation of his misinformation and lies.”

March 31, 2025

3 min read

Heather McKenzie

Blood transfusion from person to person, art collage.

Approvals

Sanofi, Alnylam Win First RNAi Approval for Hemophilia A and B

Unlike other hemophilia therapies, Qfitlia is indicated for both hemophilia A and B, and can be given in patients regardless of the presence of neutralizing antibodies against clotting factor VIII or IX.

March 31, 2025

2 min read

Tristan Manalac

World heart day. Sketch style human heart. Retro halftone hands reaching out to each other. Modern collage. Valentines day banner. Healthcare medical concept. Healthy lifestyle.

Cardiovascular disease

Lilly’s RNA Silencer Lowers Key Cardiovascular Biomarker by Almost 94%

BMO Capital Markets analysts said the results potentially position lepodisiran as “one of the most durable assets in development to date” in the competitive Lp(a) space, where drugs are designed to lower the risk of cardiovascular events such as heart attack and stroke.

March 31, 2025

2 min read

Tristan Manalac